NUWIQ
-
Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A
LACHEN, Switzerland: Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated…
Read More » - Business
Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients
LACHEN, Switzerland: Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing…
Read More »